Scientists at the University of Cambridge have reported an experimental mRNA-based treatment that helped damaged mouse hearts recover some pumping function after a heart attack. The work, published in Nature Cardiovascular Research, is an early-stage result rather than a treatment ready for patients. But it points to a possible way of addressing a central limitation of current heart-failure care: medicines can reduce symptoms and slow decline, yet they do not replace heart muscle that has already been lost.
The approach is designed to briefly restart cell-division activity in heart muscle cells. In the study, researchers used mRNA therapy to temporarily activate two proteins, Myc and Cyclin T1, inside those cells. The intended effect was to encourage repair in injured heart tissue without permanently changing the cells’ genetic material.
Targeting the lost muscle
After a heart attack, part of the heart muscle is damaged when blood supply is interrupted. The surviving organ must continue to pump with less effective tissue, a process that can contribute to heart failure. The researchers’ premise is that a treatment capable of prompting heart muscle cells to divide could help restore some of that lost capacity.
In the mouse experiments, the mRNA treatment was delivered after heart attack damage. The researchers reported that treated animals had a stronger heartbeat and pumped about 10% more blood with each beat than mice that received a mock treatment. The report characterizes the gain as partial repair, not a complete cure.
That distinction matters. A modest improvement in cardiac function can still be clinically meaningful if it eventually translates to people, because even small improvements in heart performance have been associated with lower mortality and a better ability to carry out everyday activities. The mouse result, however, cannot establish that the same benefit will occur in human patients.
Why mRNA is central to the strategy
The treatment uses mRNA as a temporary instruction set. Rather than attempting to make a lasting alteration, it directs cells to produce the selected proteins for a limited period. In this case, the proteins Myc and Cyclin T1 are used to promote proliferation of heart muscle cells.
Temporary activation is an important part of the research concept. The team is not presenting the work as a means to create unlimited growth in heart tissue; it is investigating whether a controlled, time-limited signal can help damaged cells participate in repair. Images accompanying the study showed proteins activated in mouse heart tissue and cells in the process of division.
The research also demonstrated that the mRNA therapy reached damaged areas of the mouse heart. An image taken 24 hours after injection used a modified, glowing version of the treatment to show its presence around injured heart cells. That observation supports the delivery concept, though it does not resolve the larger questions of safety, durability and effectiveness in larger animals or people.
Promising result, long development path
The authors emphasize that substantial further work is required. The next steps include refining the treatment and testing it in larger animal models before human trials could establish whether it is safe and effective for patients.
Those steps are especially consequential for a therapy that induces heart cells to divide. The source report does not claim that the technique has been proven safe beyond the experimental setting, nor does it claim a human benefit. Its significance is that it offers a potential regenerative direction for a condition where regeneration remains out of reach for standard care.
Heart failure is a major unmet medical challenge. The University of Cambridge notes that about 200,000 people in the United Kingdom are diagnosed with the condition each year. Existing treatments can help manage symptoms and slow progression, but they cannot regenerate heart muscle lost to injury.
A possible new direction for heart failure research
Dr. Catherine Wilson, an associate professor in Cambridge’s Department of Pharmacology and Gurdon Institute and a co-senior author of the study, said the results could eventually have a meaningful impact on quality of life if the approach succeeds in later testing. The researchers frame the work as an attempt to help the heart repair itself rather than solely treating the downstream effects of heart failure.
For now, the study should be read as a carefully defined preclinical advance. It provides evidence in mice that transient mRNA activation of Myc and Cyclin T1 can be associated with improved pumping after experimental heart attack damage. It does not yet show that the therapy can reverse heart failure, regenerate a human heart, or safely enter clinical use.
Still, the result gives regenerative cardiology a concrete experimental lead. If later studies can confirm a favorable safety profile, reliable delivery and a sustained functional benefit, an mRNA-based repair strategy could complement therapies that today focus primarily on preserving the function that remains.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
